Karyopharm Therapeutics (KPTI)

• Market cap: $84.1M
• 1 day: -2.98%
• 5 days: -0.54%
• 1 month: 8.15%
• 3 months: -21.68%
• 6 months: -26.87%
• Year to date: -17.89%
• 1 year: -19.87%
• 5 years: -96.13%
• 10 years: -97.47%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Employees: 325

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,266% more call options, than puts

Call options by funds: $929K | Put options by funds: $68K

6.63% less ownership

Funds ownership: 55.39% [Q2] → 48.76% (-6.63%) [Q3]

16% less capital invested

Capital invested by funds: $59.9M [Q2] → $50.4M (-$9.54M) [Q3]

20% less funds holding

Funds holding: 113 [Q2] → 90 (-23) [Q3]

28% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 29

68% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 31

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 650% upside
• Avg. target: $6 800% upside
• High target: $7 950% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 28% 1-year accuracy 41 / 147 met price target	950% upside $7	Buy Reiterated	15 Jan 2025
Piper Sandler Christopher Raymond 13% 1-year accuracy 4 / 30 met price target	650% upside $5	Overweight Maintained	6 Nov 2024